{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:20:35Z","timestamp":1790832035322,"version":"4.1.0"},"reference-count":76,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Immunol. Ther. Exp."],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Duchenne muscular dystrophy (DMD) is a lethal X-linked disease caused by mutations in the dystrophin gene, leading to muscle degeneration and wasting. Electromyography (EMG) is an objective electrophysiological biomarker of muscle fiber function in muscular dystrophies. A novel, DT-DEC01 therapy, consisting of Dystrophin Expressing Chimeric (DEC) cells created by fusing allogeneic myoblasts from normal donors with autologous myoblasts from DMD-affected patients, was assessed for safety and preliminary efficacy in boys of age 6\u201315 years old (<jats:italic>n<\/jats:italic>\u2009=\u20093). Assessments included EMG testing of selected muscles of upper (deltoideus, biceps brachii) and lower (rectus femoris and gastrocnemius) extremities at the screening visit and at 3, 6, and 12\u00a0months following systemic\u2013intraosseous administration of a single low dose of DT-DEC01 therapy (Bioethics Committee approval no. 46\/2019). No immunosuppression was administered. Safety of DT-DEC01 was confirmed by the lack of therapy-related Adverse Events or Serious Adverse Events up to 22 months following DT-DEC01 administration. EMG of selected muscles of both, ambulatory and non-ambulatory patients confirmed preliminary efficacy of DT-DEC01 therapy by an increase in motor unit potentials (MUP) duration, amplitudes, and polyphasic MUPs at 12 months. This study confirmed EMG as a reliable and objective biomarker of functional assessment in DMD patients after intraosseous administration of the novel DT-DEC01 therapy.<\/jats:p>","DOI":"10.1007\/s00005-023-00691-y","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T09:02:21Z","timestamp":1700816541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12\u00a0Months After Systemic\u2013Intraosseous Administration"],"prefix":"10.2478","volume":"71","author":[{"given":"Adam","family":"Niezgoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Biega\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Wachowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Czarnota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Siemionow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlke","family":"Heydemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ziemiecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria H.","family":"Sikorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Bo\u017cyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-6122","authenticated-orcid":false,"given":"Maria","family":"Siemionow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"691_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3233\/JND-180357","volume":"6","author":"A Aartsma-Rus","year":"2019","unstructured":"Aartsma-Rus A, Morgan J, Lonkar P et al (2019) Report of a TREAT-NMD\/world Duchenne organisation meeting on Dystrophin quantification methodology. J Neuromuscul Dis 6:147\u2013159. https:\/\/doi.org\/10.3233\/JND-180357","journal-title":"J Neuromuscul Dis"},{"key":"691_CR2","unstructured":"Acibadem University (2014) Efficacy of Umbilical cord mesenchymal stem cells in Duchenne muscular dystrophy: phase 1\/2 study. Clinical trial registration NCT02285673. clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02285673. Accessed 11 Sep 2023"},{"key":"691_CR3","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1212\/WNL.0000000000001025","volume":"83","author":"K Anthony","year":"2014","unstructured":"Anthony K, Arechavala-Gomeza V, Taylor LE et al (2014) Dystrophin quantification: biological and translational research implications. Neurology 83:2062\u20132069. https:\/\/doi.org\/10.1212\/WNL.0000000000001025","journal-title":"Neurology"},{"key":"691_CR4","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1378\/chest.07-0458","volume":"132","author":"DJ Birnkrant","year":"2007","unstructured":"Birnkrant DJ, Panitch HB, Benditt JO et al (2007) American college of chest physicians consensus statement on the respiratory and related management of patients with duchenne muscular dystrophy undergoing anesthesia or sedation. Chest 132:1977\u20131986. https:\/\/doi.org\/10.1378\/chest.07-0458","journal-title":"Chest"},{"issue":"S43","key":"691_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1600-0404.1970.tb02179.x","volume":"46","author":"F Buchthal","year":"1970","unstructured":"Buchthal F (1970) Electrophysiological abnormalities in metabolic myopathies and neuropathies. Acta Neurol Scand 46(S43):129\u2013176. https:\/\/doi.org\/10.1111\/j.1600-0404.1970.tb02179.x","journal-title":"Acta Neurol Scand"},{"key":"691_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1212\/WNL.3.6.424","volume":"3","author":"F Buchthal","year":"1953","unstructured":"Buchthal F, Pinelli P (1953) Muscle action potentials in polymyositis. Neurology 3:424\u2013436. https:\/\/doi.org\/10.1212\/WNL.3.6.424","journal-title":"Neurology"},{"key":"691_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, David J, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:77\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(09)70271-6","journal-title":"Lancet Neurol"},{"key":"691_CR8","unstructured":"Capricor Inc. (2023) Open-label extension of the HOPE-2 Duchenne muscular dystrophy trial. Clinical trial registration NCT04428476. clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04428476. Accessed 11 Sep 2023"},{"key":"691_CR9","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM et al (2020) Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol 77:982\u2013991. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1264","journal-title":"JAMA Neurol"},{"key":"691_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3233\/JND-220811","volume":"9","author":"PR Clemens","year":"2022","unstructured":"Clemens PR, Rao VK, Connolly AM et al (2022) Long-Term functional efficacy and safety of viltolarsen in patients with Duchenne muscular dystrophy. J Neuromuscul Dis 9:493\u2013501. https:\/\/doi.org\/10.3233\/JND-220811","journal-title":"J Neuromuscul Dis"},{"key":"691_CR11","doi-asserted-by":"publisher","unstructured":"Crone C, Krarup C (2013) Chapter 6 - Neurophysiological approach to disorders of peripheral nerve. In: Handbook of clinical neurology, vol 115. Elsevier, pp 81\u2013114. https:\/\/doi.org\/10.1016\/B978-0-444-52902-2.00006-0","DOI":"10.1016\/B978-0-444-52902-2.00006-0"},{"key":"691_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950651","volume":"13","author":"J Deng","year":"2022","unstructured":"Deng J, Zhang J, Shi K et al (2022) Drug development progress in Duchenne muscular dystrophy. Front Pharmacol 13:950651. https:\/\/doi.org\/10.3389\/fphar.2022.950651","journal-title":"Front Pharmacol"},{"key":"691_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/mus.22341","volume":"45","author":"KL Derry","year":"2012","unstructured":"Derry KL, Venance SL, Doherty TJ (2012) Decomposition-based quantitative electromyography in the evaluation of muscular dystrophy severity. Muscle Nerve 45:507\u2013513. https:\/\/doi.org\/10.1002\/mus.22341","journal-title":"Muscle Nerve"},{"key":"691_CR14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1089\/hum.2018.012","volume":"29","author":"D Duan","year":"2018","unstructured":"Duan D (2018) Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients. Hum Gene Ther 29:733\u2013736. https:\/\/doi.org\/10.1089\/hum.2018.012","journal-title":"Hum Gene Ther"},{"issue":"s2","key":"691_CR15","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.3233\/JND-210678","volume":"8","author":"N Elangkovan","year":"2021","unstructured":"Elangkovan N, Dickson G (2021) Gene therapy for duchenne muscular dystrophy. J Neuromuscul Dis 8(s2):S303\u2013S316. https:\/\/doi.org\/10.3233\/JND-210678","journal-title":"J Neuromuscul Dis"},{"key":"691_CR16","unstructured":"FDA Briefing Document BLA# 125781\/00 (2023) Drug name: Delandistrogene Moxeparvovec applicant: Sarepta Therapeutics, Inc. Cellular, tissue and gene therapies advisory committee meeting 05\/12\/2023 office of therapeutic products (OTP)\/CBER. Available Online. https:\/\/www.fda.gov\/media\/168021\/download. Accessed 11 Sep 2023, 19 July 2023"},{"key":"691_CR17","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clinbiomech.2008.07.012","volume":"24","author":"C Frigo","year":"2009","unstructured":"Frigo C, Crenna P (2009) Multichannel SEMG in clinical gait analysis: a review and state-of-the-art. Clin Biochem 24:236\u2013245. https:\/\/doi.org\/10.1016\/j.clinbiomech.2008.07.012","journal-title":"Clin Biochem"},{"key":"691_CR18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.nmd.2013.05.006","volume":"23","author":"N Goemans","year":"2013","unstructured":"Goemans N, van den Hauwe M, Wilson R et al (2013) Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscul Disord 23:618\u2013623. https:\/\/doi.org\/10.1016\/j.nmd.2013.05.006","journal-title":"Neuromuscul Disord"},{"key":"691_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12871-019-0887-3","volume":"19","author":"U Gurunathan","year":"2019","unstructured":"Gurunathan U, Kunju SM, Stanton LM (2019) Use of sugammadex in patients with neuromuscular disorders: a systematic review of case reports. BMC Anesthesiol 19:213. https:\/\/doi.org\/10.1186\/s12871-019-0887-3","journal-title":"BMC Anesthesiol"},{"key":"691_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1460-9592.2007.02302.x","volume":"18","author":"J Hayes","year":"2007","unstructured":"Hayes J, Veyckemans F, Bissonnette B (2007) Duchenne muscular dystrophy: an old anesthesia problem revisited. Pediatr Anesth 18:100\u2013106. https:\/\/doi.org\/10.1111\/j.1460-9592.2007.02302.x","journal-title":"Pediatr Anesth"},{"key":"691_CR21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.bja.2018.12.025","volume":"122","author":"S Hemphill","year":"2019","unstructured":"Hemphill S, McMenamin L, Bellamy MC et al (2019) Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth 122:448\u2013459. https:\/\/doi.org\/10.1016\/j.bja.2018.12.025","journal-title":"Br J Anaesth"},{"key":"691_CR23","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3390\/biomedicines11030830","volume":"11","author":"A Heydemann","year":"2023","unstructured":"Heydemann A, Siemionow M (2023) A brief review of Duchenne muscular dystrophy treatment options, with an emphasis on two novel strategies. Biomedicines 11:830. https:\/\/doi.org\/10.3390\/biomedicines11030830","journal-title":"Biomedicines"},{"key":"691_CR22","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s12015-023-10530-4","volume":"19","author":"A Heydemann","year":"2023","unstructured":"Heydemann A, Bieganski G, Wachowiak J et al (2023) Dystrophin expressing chimeric (DEC) cell therapy for Duchenne muscular dystrophy: a first-in-human study with minimum 6 months follow-up. Stem Cell Rev Rep 19:1340\u20131359. https:\/\/doi.org\/10.1007\/s12015-023-10530-4","journal-title":"Stem Cell Rev Rep"},{"key":"691_CR24","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/s41431-021-00811-2","volume":"29","author":"V Himi\u010d","year":"2021","unstructured":"Himi\u010d V, Davies KE (2021) Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophy. Eur J Hum Genet 29:1369\u20131376. https:\/\/doi.org\/10.1038\/s41431-021-00811-2","journal-title":"Eur J Hum Genet"},{"key":"691_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028209","volume":"100","author":"Y Horikoshi","year":"2021","unstructured":"Horikoshi Y, Kuratani N, Tateno K et al (2021) Anesthetic management with remimazolam for a pediatric patient with Duchenne muscular dystrophy. Medicine 100:e28209. https:\/\/doi.org\/10.1097\/MD.0000000000028209","journal-title":"Medicine"},{"key":"691_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12984-020-00757-4","volume":"17","author":"MMHP Janssen","year":"2020","unstructured":"Janssen MMHP, Peeters LHC, de Groot IJM (2020) Quantitative description of upper extremity function and activity of people with spinal muscular atrophy. J Neuroeng Rehabil 17:126. https:\/\/doi.org\/10.1186\/s12984-020-00757-4","journal-title":"J Neuroeng Rehabil"},{"key":"691_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/B978-0-323-02899-8.50007-0","volume-title":"Electromyography in clinical practice","author":"B Katirji","year":"2007","unstructured":"Katirji B (2007) Chapter 2: Routine clinical electromyography. Electromyography in clinical practice. Elsevier, Amsterdam, pp 13\u201336. https:\/\/doi.org\/10.1016\/B978-0-323-02899-8.50007-0"},{"key":"691_CR28","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1001\/jama.2016.16437","volume":"316","author":"AS Kesselheim","year":"2016","unstructured":"Kesselheim AS, Avorn J (2016) Approving a problematic muscular dystrophy drug: Implications for FDA policy. JAMA 316:2357. https:\/\/doi.org\/10.1001\/jama.2016.16437","journal-title":"JAMA"},{"key":"691_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/JND-170272","volume":"5","author":"TB Kinane","year":"2018","unstructured":"Kinane TB, Mayer OH, Duda PW et al (2018) Long-term pulmonary function in Duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history. J Neuromuscul Dis 5:47\u201358. https:\/\/doi.org\/10.3233\/JND-170272","journal-title":"J Neuromuscul Dis"},{"key":"691_CR30","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3390\/cells9051119","volume":"9","author":"A Klimczak","year":"2020","unstructured":"Klimczak A, Zimna A, Malcher A et al (2020) Co-transplantation of bone marrow-MSCs and myogenic stem\/progenitor cells from adult donors improves muscle function of patients with Duchenne muscular dystrophy. Cells 9:1119. https:\/\/doi.org\/10.3390\/cells9051119","journal-title":"Cells"},{"key":"691_CR31","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/acn3.51235","volume":"7","author":"H Komaki","year":"2020","unstructured":"Komaki H, Takeshima Y, Matsumura T et al (2020) Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase 1\/2 study. Ann Clin Transl Neurol 7:2393\u20132408. https:\/\/doi.org\/10.1002\/acn3.51235","journal-title":"Ann Clin Transl Neurol"},{"key":"691_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12984-017-0292-4","volume":"14","author":"J Lobo-Prat","year":"2017","unstructured":"Lobo-Prat J, Janssen MMHP, Koopman BFJM et al (2017) Surface EMG signals in very late-stage of Duchenne muscular dystrophy: a case study. J Neuroeng Rehabil 14:86. https:\/\/doi.org\/10.1186\/s12984-017-0292-4","journal-title":"J Neuroeng Rehabil"},{"key":"691_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44178","volume":"5","author":"JK Mah","year":"2022","unstructured":"Mah JK, Clemens PR, Guglieri M et al (2022) Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial. JAMA Netw Open 5:e2144178. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.44178","journal-title":"JAMA Netw Open"},{"key":"691_CR34","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/dmcn.12213","volume":"55","author":"A Mayhew","year":"2013","unstructured":"Mayhew A, Mazzone ES, Eagle M et al (2013) Development of the performance of the upper limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 55:1038\u20131045. https:\/\/doi.org\/10.1111\/dmcn.12213","journal-title":"Dev Med Child Neurol"},{"key":"691_CR35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/dmcn.14361","volume":"62","author":"AG Mayhew","year":"2020","unstructured":"Mayhew AG, Coratti G, Mazzone ES et al (2020) Performance of upper limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 62:633\u2013639. https:\/\/doi.org\/10.1111\/dmcn.14361","journal-title":"Dev Med Child Neurol"},{"key":"691_CR36","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.nmd.2009.06.368","volume":"19","author":"ES Mazzone","year":"2009","unstructured":"Mazzone ES, Messina S, Vasco G et al (2009) Reliability of the north star ambulatory assessment in a multicentric setting. Neuromuscul Disord 19:458\u2013461. https:\/\/doi.org\/10.1016\/j.nmd.2009.06.368","journal-title":"Neuromuscul Disord"},{"key":"691_CR37","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.nmd.2010.06.014","volume":"20","author":"E Mazzone","year":"2010","unstructured":"Mazzone E, Martinelli D, Berardinelli A et al (2010) North star ambulatory assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 20:712\u2013716. https:\/\/doi.org\/10.1016\/j.nmd.2010.06.014","journal-title":"Neuromuscul Disord"},{"key":"691_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052512","volume":"8","author":"ES Mazzone","year":"2013","unstructured":"Mazzone ES, Pane M, Sormani MP et al (2013) 24 Month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS ONE 8:e52512. https:\/\/doi.org\/10.1371\/journal.pone.0052512","journal-title":"PLoS ONE"},{"key":"691_CR39","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/mus.21808","volume":"42","author":"CM McDonald","year":"2010","unstructured":"McDonald CM, Henricson EK, Han JJ et al (2010) The 6-minute walk test in Duchenne\/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 42:966\u2013974. https:\/\/doi.org\/10.1002\/mus.21808","journal-title":"Muscle Nerve"},{"key":"691_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/mus.23905","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT et al (2013) The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48:357\u2013368. https:\/\/doi.org\/10.1002\/mus.23905","journal-title":"Muscle Nerve"},{"key":"691_CR41","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(22)00012-5","volume":"399","author":"CM McDonald","year":"2022","unstructured":"McDonald CM, Marb\u00e1n E, Hendrix S et al (2022) Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 399:1049\u20131058. https:\/\/doi.org\/10.1016\/S0140-6736(22)00012-5","journal-title":"Lancet"},{"key":"691_CR42","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell JR, Goemans N, Lowes LP et al (2016) Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy: eteplirsen in DMD. Ann Neurol 79:257\u2013271. https:\/\/doi.org\/10.1002\/ana.24555","journal-title":"Ann Neurol"},{"key":"691_CR43","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell JR, Sahenk Z, Lehman K et al (2020) Assessment of systemic delivery of rAAVrh74.MHCK7. Micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol 77:1122. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1484","journal-title":"JAMA Neurol"},{"key":"691_CR44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/EJA.0b013e3283566789","volume":"29","author":"T Muenster","year":"2012","unstructured":"Muenster T, Mueller C, Forst J et al (2012) Anaesthetic management in patients with Duchenne muscular dystrophy undergoing orthopaedic surgery: a review of 232 cases. Eur J Anaesthesiol 29:489\u2013494. https:\/\/doi.org\/10.1097\/EJA.0b013e3283566789","journal-title":"Eur J Anaesthesiol"},{"key":"691_CR45","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1089\/scd.2016.0136","volume":"25","author":"LA Muir","year":"2016","unstructured":"Muir LA, Murry CE, Chamberlain JS (2016) Prosurvival factors improve functional engraftment of myogenically converted dermal cells into dystrophic skeletal muscle. Stem Cells Dev 25:1559\u20131569. https:\/\/doi.org\/10.1089\/scd.2016.0136","journal-title":"Stem Cells Dev"},{"key":"691_CR46","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fneur.2020.00231","volume":"11","author":"K Nizamis","year":"2020","unstructured":"Nizamis K, Rijken NHM, van Middelaar R et al (2020) Characterization of forearm muscle activation in duchenne muscular dystrophy via high-density electromyography: a case study on the implications for myoelectric control. Front Neurol 11:231. https:\/\/doi.org\/10.3389\/fneur.2020.00231","journal-title":"Front Neurol"},{"key":"691_CR47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.pmr.2012.08.017","volume":"24","author":"S Paganoni","year":"2013","unstructured":"Paganoni S, Amato A (2013) Electrodiagnostic evaluation of myopathies. Phys Med Rehabil Clin N Am 24:193\u2013207. https:\/\/doi.org\/10.1016\/j.pmr.2012.08.017","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"691_CR48","unstructured":"Pfizer (2023) A Phase 2, multicenter, single-arm study to evaluate the safety and dystrophin expression after fordadistrogene movaparvovec (PF-06939926) administration in male participants with early stage Duchenne muscular dystrophy. Clinical trial registration NCT05429372. clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05429372. Accessed 8 Sep 2023"},{"key":"691_CR49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/B978-1-4557-2672-1.00015-5","volume-title":"Electromyography and neuromuscular disorders","author":"DC Preston","year":"2013","unstructured":"Preston DC, Shapiro BE (2013) 15 - Basic electromyography: analysis of motor unit action potentials. Electromyography and neuromuscular disorders. Elsevier, Amsterdam, pp 235\u2013248. https:\/\/doi.org\/10.1016\/B978-1-4557-2672-1.00015-5"},{"key":"691_CR50","unstructured":"ReveraGen BioPharma, Inc. (2021) A 24-month phase II open-label, multicenter long-term extension study to assess the long-term safety and efficacy of vamorolone in boys with Duchenne muscular dystrophy (DMD). Clinical trial registration NCT03038399. clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03038399. Accessed 11 Sep 2023"},{"key":"691_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161938","volume":"11","author":"J Ropars","year":"2016","unstructured":"Ropars J, Lempereur M, Vuillerot C et al (2016) Muscle activation during gait in children with Duchenne muscular dystrophy. PLoS ONE 11:e0161938. https:\/\/doi.org\/10.1371\/journal.pone.0161938","journal-title":"PLoS ONE"},{"key":"691_CR52","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1016\/j.clinph.2005.01.017","volume":"116","author":"K Rowinska-Marcinska","year":"2005","unstructured":"Rowinska-Marcinska K, Szmid-Sa\u0142kowska E, Fidzianska A et al (2005) Atypical motor unit potentials in Emery-Dreifuss muscular dystrophy (EDMD). Clin Neurophysiol 116:2520\u20132527. https:\/\/doi.org\/10.1016\/j.clinph.2005.01.017","journal-title":"Clin Neurophysiol"},{"key":"691_CR53","unstructured":"Sarepta Therapeutics, Inc. (2020) A 2-part, randomized, double-blind, placebo-controlled, dose-titration, safety, tolerability, and pharmacokinetics study (part 1) followed by an open-label efficacy and safety evaluation (part 2) of srp-4053 in patients with Duchenne muscular dystrophy amenable to exon 53 skipping. Clinical trial registration NCT02310906. clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02310906. Accessed 8 Sep 2023"},{"key":"691_CR54","unstructured":"Sarepta Therapeutics, Inc. (2023) Systemic gene delivery phase I\/IIa clinical trial for Duchenne muscular dystrophy using rAAVrh74.MHCK7. Micro-Dystrophin (microDys-IV-001). Clinical trial registration NCT03375164. clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03375164. Accessed 8 Sep 2023"},{"key":"691_CR55","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","volume":"126","author":"P Schober","year":"2018","unstructured":"Schober P, Boer C, Schwarte LA (2018) Correlation coefficients: appropriate use and interpretation. Anesth Analg 126:1763\u20131768. https:\/\/doi.org\/10.1213\/ANE.0000000000002864","journal-title":"Anesth Analg"},{"key":"691_CR56","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/pan.12248","volume":"23","author":"LG Segura","year":"2013","unstructured":"Segura LG, Lorenz JD, Weingarten TN et al (2013) Anesthesia and Duchenne or Becker muscular dystrophy: review of 117 anesthetic exposures. Pediatr Anesth 23:855\u2013864. https:\/\/doi.org\/10.1111\/pan.12248","journal-title":"Pediatr Anesth"},{"key":"691_CR57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/nat.2021.0043","volume":"32","author":"L Servais","year":"2022","unstructured":"Servais L, Mercuri E, Straub V et al (2022) Long-term safety and efficacy data of golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial. Nucleic Acid Ther 32:29\u201339. https:\/\/doi.org\/10.1089\/nat.2021.0043","journal-title":"Nucleic Acid Ther"},{"key":"691_CR58","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13023-018-0834-2","volume":"13","author":"Y Shimizu-Motohashi","year":"2018","unstructured":"Shimizu-Motohashi Y, Murakami T, Kimura E et al (2018) Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis. Orphanet J Rare Dis 13:93. https:\/\/doi.org\/10.1186\/s13023-018-0834-2","journal-title":"Orphanet J Rare Dis"},{"key":"691_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm9010001","volume":"9","author":"Y Shimizu-Motohashi","year":"2019","unstructured":"Shimizu-Motohashi Y, Komaki H, Motohashi N et al (2019) Restoring dystrophin expression in Duchenne muscular dystrophy: current status of therapeutic approaches. J Pers Med 9:1. https:\/\/doi.org\/10.3390\/jpm9010001","journal-title":"J Pers Med"},{"key":"691_CR60","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12015-017-9792-7","volume":"14","author":"M Siemionow","year":"2018","unstructured":"Siemionow M, Cwykiel J, Heydemann A et al (2018a) Creation of dystrophin expressing chimeric cells of myoblast origin as a novel stem cell based therapy for Duchenne muscular dystrophy. Stem Cell Rev Rep 14:189\u2013199. https:\/\/doi.org\/10.1007\/s12015-017-9792-7","journal-title":"Stem Cell Rev Rep"},{"key":"691_CR61","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12015-018-9807-z","volume":"14","author":"M Siemionow","year":"2018","unstructured":"Siemionow M, Cwykiel J, Heydemann A et al (2018b) Dystrophin expressing chimeric (DEC) human cells provide a potential therapy for Duchenne muscular dystrophy. Stem Cell Rev Rep 14:370\u2013384. https:\/\/doi.org\/10.1007\/s12015-018-9807-z","journal-title":"Stem Cell Rev Rep"},{"key":"691_CR62","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s12015-019-09916-0","volume":"15","author":"M Siemionow","year":"2019","unstructured":"Siemionow M, Malik M, Langa P et al (2019) Cardiac protection after systemic transplant of dystrophin expressing chimeric (DEC) cells to the Mdx mouse model of Duchenne muscular dystrophy. Stem Cell Rev Rep 15:827\u2013841. https:\/\/doi.org\/10.1007\/s12015-019-09916-0","journal-title":"Stem Cell Rev Rep"},{"key":"691_CR63","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1007\/s12015-022-10384-2","volume":"18","author":"M Siemionow","year":"2022","unstructured":"Siemionow M, Langa P, Brodowska S et al (2022a) Long-term protective effect of human dystrophin expressing chimeric (DEC) cell therapy on amelioration of function of cardiac, respiratory and skeletal muscles in Duchenne muscular dystrophy. Stem Cell Rev Rep 18:2872\u20132892. https:\/\/doi.org\/10.1007\/s12015-022-10384-2","journal-title":"Stem Cell Rev Rep"},{"key":"691_CR64","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00005-022-00656-7","volume":"70","author":"M Siemionow","year":"2022","unstructured":"Siemionow M, Brodowska S, Langa P et al (2022b) Long-term biodistribution and safety of human dystrophin expressing chimeric cell therapy after systemic-intraosseous administration to Duchenne muscular dystrophy model. Arch Immunol Ther Exp 70:20. https:\/\/doi.org\/10.1007\/s00005-022-00656-7","journal-title":"Arch Immunol Ther Exp"},{"key":"691_CR65","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-023-10620-3","author":"M Siemionow","year":"2023","unstructured":"Siemionow M, Biega\u0144ski G, Niezgoda A et al (2023) Safety and efficacy of DT-DEC01 therapy in Duchenne muscular dystrophy patients: A 12-month follow-up study after systemic intraosseous administration. Stem Cell Rev Rep. https:\/\/doi.org\/10.1007\/s12015-023-10620-3","journal-title":"Stem Cell Rev Rep"},{"key":"691_CR66","unstructured":"Solid Biosciences Inc. (2023) A randomized, controlled, open-label, single-ascending dose, phase I\/II study to investigate the safety and tolerability, and efficacy of intravenous SGT-001 in male adolescents and children with Duchenne muscular dystrophy. Clinical trial registration NCT03368742. clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03368742. Accessed 8 Sep 2023"},{"key":"691_CR67","unstructured":"Stem Cells Arabia (2020) Safety and efficacy of purified autologous bone marrow-derived stem cell therapy for patients with Duchenne muscular dystrophy. Clinical trial registration NCT03067831. clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03067831. Accessed 11 Sep 2023"},{"key":"691_CR68","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1136\/archdischild-2014-307962","volume":"100","author":"EM Strehle","year":"2015","unstructured":"Strehle EM, Straub V (2015) Recent advances in the management of Duchenne muscular dystrophy. Arch Dis Child 100:1173\u20131177. https:\/\/doi.org\/10.1136\/archdischild-2014-307962","journal-title":"Arch Dis Child"},{"key":"691_CR69","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pjnns.2015.05.005","volume":"49","author":"E Szmidt-Sa\u0142kowska","year":"2015","unstructured":"Szmidt-Sa\u0142kowska E, Gawe\u0142 M, Lipowska M (2015) Motor unit reorganization in progressive muscular dystrophies and congenital myopathies. Neurologia Neurochirurgia Polska 49:223\u2013228. https:\/\/doi.org\/10.1016\/j.pjnns.2015.05.005","journal-title":"Neurologia Neurochirurgia Polska"},{"key":"691_CR70","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mus.27323","volume":"64","author":"JP Trost","year":"2021","unstructured":"Trost JP, Chen M, Stark MM et al (2021) Voluntary and magnetically evoked muscle contraction protocol in males with Duchenne muscular dystrophy: safety, feasibility, reliability, and validity. Muscle Nerve 64:190\u2013198. https:\/\/doi.org\/10.1002\/mus.27323","journal-title":"Muscle Nerve"},{"key":"691_CR71","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1111\/ene.15526","volume":"29","author":"LR van den Bersselaar","year":"2022","unstructured":"van den Bersselaar LR, Heytens L, Silva HCA et al (2022) European neuromuscular centre consensus statement on anaesthesia in patients with neuromuscular disorders. Eur J Neurol 29:3486\u20133507. https:\/\/doi.org\/10.1111\/ene.15526","journal-title":"Eur J Neurol"},{"key":"691_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238445","volume":"15","author":"I Vandekerckhove","year":"2020","unstructured":"Vandekerckhove I, De Beukelaer N, Van den Hauwe M et al (2020) Muscle weakness has a limited effect on motor control of gait in Duchenne muscular dystrophy. PLoS ONE 15:e0238445. https:\/\/doi.org\/10.1371\/journal.pone.0238445","journal-title":"PLoS ONE"},{"key":"691_CR73","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/mus.25678","volume":"56","author":"S Verma","year":"2017","unstructured":"Verma S, Lin J, Travers C et al (2017) Quantitative electromyography in ambulatory boys with Duchenne muscular dystrophy. Muscle Nerve 56:1168\u20131171. https:\/\/doi.org\/10.1002\/mus.25678","journal-title":"Muscle Nerve"},{"key":"691_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.689533","volume":"9","author":"S Yao","year":"2021","unstructured":"Yao S, Chen Z, Yu Y et al (2021) Current pharmacological strategies for Duchenne muscular dystrophy. Front Cell Dev Biol 9:689533. https:\/\/doi.org\/10.3389\/fcell.2021.689533","journal-title":"Front Cell Dev Biol"},{"key":"691_CR75","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1460-9592.2005.01801.x","volume":"16","author":"TA Yemen","year":"2006","unstructured":"Yemen TA, Mcclain C (2006) Muscular dystrophy, anesthesia and the safety of inhalational agents revisited; again. Pediatr Anesth 16:105\u2013108. https:\/\/doi.org\/10.1111\/j.1460-9592.2005.01801.x","journal-title":"Pediatr Anesth"},{"key":"691_CR76","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jelekin.2012.11.002","volume":"23","author":"E Zalewska","year":"2013","unstructured":"Zalewska E, Szmidt-Salkowska E, Rowinska-Marcinska K et al (2013) Motor unit potentials with satellites in dystrophinopathies. J Electromyogr Kinesiol 23:580\u2013586. https:\/\/doi.org\/10.1016\/j.jelekin.2012.11.002","journal-title":"J Electromyogr Kinesiol"}],"container-title":["Archivum Immunologiae et Therapiae Experimentalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-023-00691-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00005-023-00691-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-023-00691-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T20:50:06Z","timestamp":1704228606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00005-023-00691-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["691"],"URL":"https:\/\/doi.org\/10.1007\/s00005-023-00691-y","relation":{},"ISSN":["0004-069X","1661-4917"],"issn-type":[{"value":"0004-069X","type":"print"},{"value":"1661-4917","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]},"assertion":[{"value":"11 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS is CMO and shareholder of Dystrogen Therapeutics Corp. the company that holds a license for DT-DEC01 therapy. MS is the inventor on the patent application filed by University of Illinois at Chicago related to chimeric cell therapy for Duchenne muscular dystrophy (WO\/2016\/201182). The author declares a potential conflict of interest. KS is CEO and shareholder of Dystrogen Therapeutics Corp. AH is the adviser to Dystrogen Therapeutics Corp. The authors declare a potential conflict of interest. AN, GB, JW and JC received fees for work related to this study. AZ, MHS and KB are Dystrogen Therapeutics Corp. employees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and the Good Clinical Practice (GCP) guidelines. The study protocol (DT-DEC01-DMD) was approved by the Bioethics Committee at the Regional Medical Council in Poznan, Poland (approval No. 46\/2019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}],"article-number":"24"}}